Mark Sawicki Sells 3,235 Shares of CryoPort (NASDAQ:CYRX) Stock

CryoPort, Inc. (NASDAQ:CYRX) insider Mark Sawicki sold 3,235 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $25,880.00. Following the completion of the sale, the insider owned 103,697 shares of the company’s stock, valued at $829,576. The trade was a 3.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

CryoPort Stock Down 2.9%

CYRX opened at $8.12 on Thursday. The stock’s fifty day moving average is $9.14 and its two-hundred day moving average is $9.35. The company has a market capitalization of $404.86 million, a P/E ratio of 6.15 and a beta of 1.69. CryoPort, Inc. has a 52 week low of $4.63 and a 52 week high of $11.45.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%.The firm had revenue of $45.45 million during the quarter, compared to analysts’ expectations of $42.92 million. Equities analysts anticipate that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on CYRX shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th. Wall Street Zen downgraded shares of CryoPort from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Needham & Company LLC boosted their price target on shares of CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.94.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Mak Capital One LLC purchased a new stake in shares of CryoPort during the 3rd quarter worth $7,756,000. UBS Group AG grew its stake in CryoPort by 112.7% in the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock valued at $12,623,000 after purchasing an additional 705,649 shares during the last quarter. Millennium Management LLC grew its stake in CryoPort by 23.8% in the fourth quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock valued at $31,150,000 after purchasing an additional 623,896 shares during the last quarter. Kennedy Capital Management LLC bought a new position in CryoPort in the second quarter worth about $4,084,000. Finally, Assenagon Asset Management S.A. lifted its position in shares of CryoPort by 37.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock valued at $14,208,000 after buying an additional 408,263 shares during the last quarter. 92.90% of the stock is owned by institutional investors.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.